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Introduction: Malignant pleural mesothelioma (MM) is an aggres-
sive asbestos-associated malignancy with limited therapeutic 
options. This study describes the overexpression of Ephrin B2 recep-
tor (EPHB2) in MM cell lines and tumors, and the effect of its manip-
ulation on proliferative and invasive qualities of the disease.
Methods: Using expression arrays, we investigated EPHB2 in MM 
tumors compared with normal mesothelium. EPHB2 and down-
stream target expression were evaluated using reverse-transcriptase 
polymerase chain reaction and immunoblotting methods. The bio-
logical significance of EPHB2 in MM was evaluated using in vitro 
functional assays with and without targeting by EPHB2-short hairpin 
RNA or blocking peptide in two mesothelioma cell lines, HP-1 and 
H2595.
Results: EPHB2 is overexpressed in all MM cell lines, but not in 
benign mesothelial cells, and is significantly elevated in MM tumor 
tissue compared with matched normal peritoneum. Targeted knock-
down of EPHB2 in HP-1 and H2595 cell lines reduced its expression 
and that of EPHB2 downstream targets such as matrix metalloprotein-
ase (MMP-2) and vascular endothelial growth factor, whereas cas-
pase 2 and caspase 8 had increased expression. Inhibition of EPHB2 
resulted in a significant decrease in scratch closure (1.25-fold–1.8-
fold), proliferation (1.5-fold), and invasion (1.7-fold–1.8-fold) com-
pared with the controls. Most notably, however, EPHB2 silencing 
resulted in a significant increase in apoptotic proteins and activity.
Conclusion: EPHB2 seems to play an important role in MM patho-
genesis and these findings indicate that EPHB2 could serve as a 
potential novel therapeutic target for treatment of the disease.
Key Words: Mesothelioma, Ephrin receptor B2, Invasion, 
Proliferation, Apoptosis.
(J Thorac Oncol. 2013;8: 1203-1211)
Malignant mesothelioma (MM) is a rare asbestos-induced, aggressive neoplasm that most often arises 
from the serous surface of the pleural and peritoneal cavity, 
and is associated with a poor prognosis.1,2 It is relatively rare 
in the United States, about 2500 to 3000 cases are diagnosed 
each year and the majority are diagnosed in late stages when 
the disease shows a high resistance to all types of conven-
tional treatments such as surgery, chemotherapy, and radio-
therapy.3 Despite advances in the treatment of MM, the 
median survival remains 12 months from the time of diag-
nosis. Increased understanding of the molecular basis for the 
diverse signaling pathways involved in cancer progression 
should promote the discovery of novel biomarkers for early 
diagnosis and potentially lead to more effective therapeutic 
tools for the disease.
Ephrin (EPH) receptors and their ligands constitute the 
largest subfamily of receptor tyrosine kinases (RTKs) and are 
critical to a wide range of cellular processes during embry-
onic development, cell aggregation and migration, segmenta-
tion, neural development, angiogenesis, vascular hierarchical 
remodeling, and cytoskeleton alterations.4–7 The EPH family 
members are subdivided by sequence identity into A class and 
B class according to their binding capacities with correspond-
ing ligands.8
EPH-RTK signaling regulates cancer initiation and 
metastatic progression through multiple mechanisms, and 
signaling events activated by their corresponding ligands 
may be bidirectional, forward, or a reverse manner.9 In 
fact, the literature on tumor-cell autonomous effects of 
EPH receptors demonstrates a dual role for tumor suppres-
sion and tumor promotion.10–14 The complex nature of EPH 
receptor signaling and crosstalk with other RTKs pres-
ents a unique challenge as well as opportunity to develop 
novel strategies for targeting malignancy. EPH receptors 
and ligand overexpression in a variety of human cancers 
correlates with cancer progression,4,9 with some studies 
implicating effects on the angiogenic pathways15–20 and 
apoptosis.21,22 In the current study, we examined the expres-
sion of the Ephrin B2 receptor (EPHB2) in tumor and cor-
responding normal peritoneum, as well as in benign and 
MM cell lines. We report that silencing the EPHB2 gene 
expression in MM cell lines decreased its protein expres-
sion, resulted in a significant decrease in cell prolifera-
tion, migration, colony formation, as well as an increase 
in apoptosis-related caspase-8 activity. Further, the use of 
an EPHB2-blocking peptide altered proliferation and cell 
invasion of mesothelioma cells.
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MATERIALS AND METHODS
Cell Lines
MM cell lines HP1, HP3, H2373, H2452, H2591, 
H2595, H2596, and H2461, tert immortalized mesothelial cell 
line LP9,23 primary mesothelial cell culture NYU590.2 (pas-
sage 3), and simian virus 40 (SV40)-transformed mesothelial 
cell line Met5A were grown in 1X Dulbecco’s Modified Eagle 
Medium (DMEM; Invitrogen, Grand Island, NY) contain-
ing 10% fetal bovine serum (FBS; Invitrogen) and pencillin/
streptomycin (Invitrogen, Carlsbad, CA). Human mesothelial 
cells (NYU590.2) were surgically isolated from a noncancer 
patient.
Clinical Specimens
Thirty-four matched MM tumors and normal peri-
tonea from patients undergoing extrapleural pneumonec-
tomy were used for differential gene-expression analysis of 
EPHB2 using human genome 1.0 ST (HG 1.0ST) microar-
ray chips (Affymetrix Inc., Santa Clara, CA). Expression 
data was validated by quantitative real-time polymerase 
chain reaction (qRT-PCR) and Western blot analysis using 
RNA and protein lysate from seven matched tumor/normal 
tissue pairs as previously described.24
RNA Extraction
Cell lines and tissue RNA were extracted using RNEasy 
Mini Kit from Qiagen (QIAGEN Inc., Valencia, CA) follow-
ing manufacturer’s protocol.
Semiquantitative RT-PCR
Semiquantitative RT-PCR analysis was performed using 
SuperScript III One-Step PCR Kit (Invitrogen). For the 
detection of EPHB2, gene-specific primers, 5′-CTTC-
GAGGCCGTTGAGAAT-3′ (forward) and 5′-GAGCC-
ACAGCTCTTGCAGAT-3′ (reverse) spanning at least two exons 
were designed based on National Center for Biotechnology 
Information (NCBI) gene bank sequences (NM_017449.3) 
annealing at 58°C for 30 cycles. The PCR products were sub-
jected to electrophoresis in 1.5% agarose gels stained with ethid-
ium bromide.
Quantitative Real-Time Polymerase 
Chain Reaction Analysis
The mRNA was quantitatively measured by using Step-
One real-time PCR System (Applied Biosystems, Carlsbad, 
CA). Superscript III First Strand Synthesis Super Mix 
(Invitrogen) was used to generate first strand cDNA. Samples 
were assayed in 20-µl reaction mixture containing 50 ng of 
cDNA, 200 nM of gene-specific primers (Table 1), 2X SYBR 
Green Master Mix (Life Technologies, Grand Island, NY) and 
molecular grade H
2
O. The amplifications were performed for 
40 cycles at 58°C for 1 minute. Samples were run in duplicates 
including negative controls. Relative quantification (2−∆∆CT 
method) was performed to determine the relative quantities. 
Peptidylproplyl isomerase A gene was used as a normaliza-
tion control in both semi- and quantitavie real time polymerase 
chain reaction (qRT-PCR) analysis.
Antibodies and Blocking Peptides
Actin (sc-1616), EPHB2 (sc-130752), MMP9 (sc-
13594), VEGF (sc-7269), caspase 1 (sc-515), caspase 8 
(sc-6136), BIRC5 (sc-17779), BCL2L1 (sc-7195) and 
EPHB2-blocking peptide (sc-1763P) were purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) to be used 
for the Western blotting experiments (see below).
shRNA Plasmids and Blocking 
Peptide Treatments
Two independent EPHB2-shRNA constructs containing 
a short-hairpin target sequence (NCBI Ref ID: NM_004442.6) 
of 19mers, 5′-ACCTCGTCTACAACATCAT-3’ (HSH004939-
1-LvH1) and 5′-ACCTCGTCTACAACATCAT-3′ 
(HSH004939-2-LvH1), and a scrambled control 
(CSHCTR001-LvH1) plasmids were purchased from 
GeneCopoeia (Rockville, MD). MM cell lines H2595, HP-1, 
and normal mesothelial LP9 cells were transfected with 4 
µg of either scrambled control or EPHB2-shRNA plasmids 
in a 10-cm dish for 48 hours using Lipofectamine 2000 
(Invitrogen) as recommended. Forty-eight hours posttrans-
fection, cells were used for Western blot analysis, immuno-
fluorescence, and function behavior studies as described. For 
blocking experiments, H2595 and HP-1 cells were treated 
with 0.2 and 2 µg/ml of EPHB2-blocking peptide.
TABLE 1.  Quantitative Real-Time-Polymerase Chain Reaction
Gene
NCBI Ref  
Seq No. Forward Primer Reverse Primer
Annealing 
Temp (°C)
Product
Size (bp)
EPHB2 NM_017449.3 TGGCTACGATGAGAACATGAA CTTGGTCCGTAGCCAGTTGT 58 88
Caspase1 NG_029124.1 TGCCAAATTTGCATCACATA TTCCAGATGTTTGATCTGCTG 58 85
Caspase 8 NM_001228.4 CTACATTCCGCAAAGGAAGC GGACAGATTGCTTTCCTCCA 58 97
BCL2L1 NG_029002.1 TGGAAGAGAACAGGACTGAGG AGGATGGGTTGCCATTGAT 58 81
BIRC5 NM_001168.2 GAGGCTGGCTTCATCCACT CAGCTCCTTGAAGCAGAAGA 58 75
MMP-2 NG_008989.1 CCCAAAACGGACAAAGAGTT ACAGGTTGCAGCTCTCCTTG 58 76
VEGF NM_001171623.1 AAGGAGGAGGGCAGAATCAT CTCGATTGGATGGCAGTAGC 58 77
PPIA NM_021130.3 GCTCTGAGCACTGGAGAGAAA GAAGTCACCACCCTGACACA 58 90
Gene-specific primers and optimized conditions.
EPHB2, ephrin B2 receptor, MMP-2, matrix metalloproteinase; VEGF, vascular endothelial growth factor; PPIA, peptidylproplyl isomerase.
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Western Blot Analysis
Total cell proteins were prepared by lysing the cells in 
10 mM/liter Tris (pH 7.5), 1 mM/liter EDTA, 150 mM /liter 
NaCl, 1% Triton X-100, 1 mM/liter DTT, 10% glycerol for half-
hour on ice. The lysates were centrifuged and cleared at 13K, 
and total protein was estimated by bicinchoninic acid (BCA) 
Protein Assay Kit (Thermoscientific, Rockford, IL). Twenty-
five micrograms of samples were separated on 8% to 16% 
Tris-Glycine gel (Invitrogen, Green Island, NY) and transferred 
to polyvinylidene fluoride (PVDF) membrane (Millipore, 
Billerica, MA). The membranes were blocked in 5% nonfat dry 
milk for 1 hour at room temperature followed by overnight incu-
bation in primary antibody at 4°C and then incubated in second-
ary antibody conjugated with horseradish peroxidase for 1 hour 
at room temperature. SuperSignal West Pico Chemiluminescent 
Substrate (Thermoscientific, Rockford, IL) was used to develop 
the membrane. To ensure equal loading and transfer of proteins, 
membranes were stripped and reprobed with Actin antibody.
Immunoflourescence
Scrambled control and EPHB2-shRNA plasmids trans-
fected mesothelioma cells, H2595 and HP-1 were cultured 
on Lab-Tek II 4-well chamber slides (Thermoscientific) and 
fixed in 4% paraformaldehyde in PBS (pH 7.4) for 30 min-
utes. The slides were rinsed twice in PBS and preincubated 
with blocking buffer (0.2% Triton X-100, 1% bovine serum 
albumin in PBS) for 20 minutes. The slides were then incu-
bated with primary antibodies to EPHB2 (1:100) in blocking 
buffer at 4°C overnight. After washing thrice, the slides were 
incubated with the fluorescein-conjugated secondary antibody 
(Molecular Probes, Eugene, OR). Nuclei were counterstained 
with 4′,6-diamidino-2-phenylindole, washed extensively with 
PBS, and mounted with Vectashield antifade mounting solu-
tion (Vector Laboratories, Burlingame, CA). Images were 
obtained using a Nikon Eclipse 90i fluorescence microscope 
(Nikon Instruments Inc., Melville, NY) using NIS Elements 
digital imaging software (Nikon Instruments, Inc.).
Matrigel Invasion Assay
The BD Biocoat Matrigel invasion chambers (BD 
Sciences, Franklin Lakes, NJ) were used according to the 
manufacturer’s protocol. We transferred 5 × 104 posttrans-
fected cells onto a 8 µM pore-size polycarbonate membrane 
inserts coated with a thin layer Matrigel basement membrane 
matrix without phenol-red (BD Sciences). For peptide treat-
ment, the cells were first seeded on coated inserts and then 
incubated with the blocking peptide for 48 hours at 37°C and 
5% CO
2
. The inserts were removed and noninvading cells on 
the upper surface were removed with a cotton swab. The cells 
that migrated through the Matrigel (Franklin Lakes, NJ) to the 
lower surface were fixed and stained with Giemsa solution and 
the cells were counted in five individual high-power fields for 
each membrane under a light microscope. Assays were done 
in triplicate for each treatment group.
Cell-Proliferation Assay
H2595 and HP-1 cells transfected with scrambled 
control, and EPHB2-shRNA plasmids were seeded onto 
a 96-well plate at a density of 4 × 104 cells per well in 100 
µl of DMEM/10% FBS and incubated at 37°C for 48 hours. 
For peptide treatment, cells were seeded and then incubated 
in blocking peptide. Twenty microliters of Cell-Titer-Blue 
reagent (Promega, Madison, WI) was added to each well and 
incubated for 1 hour. Optical density was measured at 560 
of 590 λ using the Universal Reader Victor3 (PerkinElmer, 
Waltham, MA).
Scratch Closure Assay
We seeded 2 × 105 transfected cells in 6-well plates. 
After 24 hours, a single scratch was made through the bot-
tom of the plate using a 1-ml sterile pipette tip. Plates were 
washed with PBS to remove floating cells. The undersides 
of plates were marked and the scratch width was measured 
at three locations. Plates were incubated for 24 hours and 
scratch width measured at the same three points in refer-
ence to marks. Closure was calculated as a percent of initial 
scratch width.
Soft-Agar Colony Formation
Plates with base agars were made before 30 minutes 
of cell seeding with equal volumes of 1% agarose and 2 × 
DMEM/10% FBS, both at 40°. A 1.5 ml of warm base agar 
was poured into 6-well plates and allowed to polymerize. The 
top agar was produced by combing equal volumes 5 × 103 
transfected cells/ml in 1×DMEM/10% FBS with warm 0.7% 
agarose. Two milliters of the agarose cell mixture was placed 
on top of each base coat. Plates were incubated at 37°C, 5% 
CO
2
 for 14 to 21 days. Colonies were stained with 0.5 ml of 
0.005% Crystal violet for more than 1 hour and counted under 
a dissecting microscope.
Caspase-8 Activity Assay
Caspase-8 activity assay was performed as described by 
the manufacturer (Genscript, Piscatway, NJ) to measure apop-
tosis. Then 3 × 105 posttransfected cells were collected and 
washed twice with 1× PBS. The cells were incubated in lysis 
buffer for 60 minutes on ice and centrifuged at 10,000 rpm 
at 4°C for 10 minutes. Clear lysate supernatant containing 
200 µg of protein was assayed using caspase-8 substrate. 
The caspase-8 activity was measured at 405 nM using a 
spectrophotometer.
Statistical Analysis
The EPHB2-dependent changes from all functional 
assays were analyzed for statistically significant differences 
by standard Student’s t test, with p value less than 0.05 consid-
ered significant. All statistical analysis were performed with 
the use of SigmaPlot, Version 8 (San Jose, CA)
RESULTS
EPHB2 Is Overexpressed in MM Tumors
Gene-expression profiles of 34 matched MPM tumors 
and normal peritoneum were established using Affymetrix 
HG 1.0ST microarrays followed by analysis of microarray 
data. We found significant (p = 2.39E-05) overexpression 
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of EPHB2 by 3.75-fold change in tumors compared with its 
normal peritoneum (Fig. 1A). A similar pattern of expres-
sion is seen on U133plus2.0 arrays (see supplementary data 
3, http://links.lww.com/JTO/A449). In reviewing EPHB2 
data in GEOPROFILES, we found confirmatory data using 
the U133 Affymetrix platform, which demonstrated a 
relative expression of normal pleura (n = 5) to be 32 rela-
tive units compared with 71 for 42 mesothelioma tumors 
(http://www.ncbi.nlm.nih.gov/geo/tools/prof ileGraph.
cgi?ID=GDS1220:209589_s_at).
We validated this data by qRT-PCR and Western blot 
analysis in seven matched tumor/normal tissue pairs from 
the same set that were used for the microarray analysis. 
Quantitative RT-PCR analysis showed a significant elevation 
in EPHB2 mRNA in tumors compared with matched normal 
peritoneum (see supplementary data, Figure 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A447). The qRT-
PCR results correlated well with the elevated levels of EPHB2 
protein in tumors seen by Western blot analysis (Fig. 1B).
EPH B2 Is Overexpressed in 
Mesothelioma Cell Lines
The expression of EpEPHB2 was evaluated in eight 
mesothelioma cell lines and two benign mesothelial cell lines 
by semiquantitative RT-PCR method. We noted an increase in 
the levels of EPHB2 mRNA expression in MM cell lines com-
pared with benign mesothelial cells (Fig. 1C). These results 
were validated by qRT-PCR (see supplementary data, Figure 
2, Supplemental Digital Content 2, http://links.lww.com/JTO/
A448).
Knockdown of EPHB2 by Its shRNA 
Decreased Its mRNA and Protein with 
an Increase in Apoptotic Cells
After validating overexpression of EPHB2 in MM tumor 
tissue and cell lines, we studied its functional behavior by 
knocking it down with a gene-specific short-hairpin sequence 
consisting of 19 bases. Two MM cell lines, H2595, HP-1, and 
one benign LP9 cell line were successfully transfected with 
EPHB2-shRNA and scrambled control plasmids for 48 hours. 
Posttransfected cells were evaluated for EPHB2 mRNA and 
protein expression by qRT-PCR and Western blot analysis. 
Both H2595 and HP-1 cells showed 80% to 90% knockdown 
of its mRNA expression (Fig. 3A). Western blot analysis 
reflected a 90% reduction in its protein levels compared with 
treated controls (Fig. 2A). The reduction in EPHB2 expres-
sion was also confirmed by immunofluorescence in both of the 
mesothelioma cell lines cultured on chamber slides (Fig. 2B).
Further analyses of downstream genes by qRT-PCR 
revealed that silencing EPHB2 with shRNA in H2595 and 
HP-1 cells resulted in significant decreases in the mRNA 
levels of matrix metalloproteinase (MMP-2), VEGF, and 
antiapoptotic genes BCL2 and BIRC5 (survivin). Moreover, 
up-regulation of apoptotic genes such as caspase 1 and cas-
pase 8 (Fig. 3A) was recorded as well, as a 30% to 40% 
increase in apoptotic cells in HP-1 and H2595 MM cells com-
pared with scrambled control (Fig. 3C). Similar changes were 
noticed in the protein of these downstream targets by Western 
blot analysis (Fig. 3B). However, no changes were recorded 
with EPHB2 knockdown in LP9 cells.
EPHB2 Suppression Is Involved in 
Decreased Cell Proliferation, Migration, 
Invasion, and Colony Formation
To study the significance of EPHB2 expression on 
the biological behavior of MM we performed a series of in 
vitro functional assays. Our results demonstrate that target-
ing EPHB2 in H2595 and HP-1 cells with shRNA resulted in 
a significant decrease in the tumorigenic properties but has 
no effect in LP9 benign mesothelial cells. In cell-proliferation 
assay, there was a 1.4-fold to 2.0-fold (p < 0.0015) decrease in 
cell density in both the MM cell lines, H2595 and HP-1, with 
EPHB2-shRNA compared with scrambled controls (Fig. 4A).
FIGURE 1.  EPHB2 is overexpressed in MM tumors and cell 
lines. A, Affymetrix HG 1.0ST microarrays reveals a 3.75-fold 
(p = 2.39E-05) increase in EPHB2 gene-expression levels 
in tumors compared with matched normal peritoneum. B, 
Western blot analysis of tissue lysates also demonstrates over-
expression of EPHB2 in clinical MM tumor specimens com-
pared with matched normal peritoneum. C, Semiquantitative 
RT-PCR analysis reveals elevated levels of EPHB2 in MM cell 
lines compared with benign cell lines. PPIA, peptidylproplyl 
isomerase; EPHB2, ephrin B2 receptor; MM, malignant meso-
thelioma; NYU, New York University.
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Cells transfected with EPHB2-shRNA plasmids had 
significant decreases in horizontal migration in a scratch clo-
sure assay. In H2595 cells, the scratch closure was reduced 
by 29% (p < 0.0005) and by 25% (p < 0.0005) in HP-1 cells 
compared with treated scrambled controls (Fig. 4B).
Silencing EPHB2 expression in H2595 and HP-1 cell 
lines significantly decreased the ability of the cells to invade 
through matrigel compared with treated scrambled control 
cells used in the studies. Both H2595 and HP-1 cells showed 
2.3-fold to 2.7-fold (p < 2.00E-05) and 1.5-fold to 1.7-fold 
(p < 2.00E-05) decrease in cell invasion (Fig. 4C). In a soft 
agar colony formation assay, EPHB2 knockdown exhibited a 
significant decrease in the size and number of colonies in both 
the cell lines at 21 days (Fig. 4D).
Blocking EPHB2 Expression by Its Peptide 
Showed a Significant Reduction in Cell 
Proliferation and Cell Invasion
In an effort to further validate the functional aspects of 
EPHB2 expression in MM, both H2595 and HP-1 cells were 
treated with immunoglobulin control or EPHB2-blocking pep-
tide using concentration of 0.2 µg/ml or 2 µg/ml. After 24 hours 
of treatment, there was a significant decrease in the cell prolif-
eration compared with the treated controls. Cells receiving 0.2 
µg/ml of the blocking peptide had a 2.1-fold (p = 0.031) and 
2.56-fold (p = 0.003) decrease in cell proliferation. At 2 µg/ml 
concentrations, there was a 2.5-fold decrease in cell prolifera-
tion in H2595 (p = 0.0002) and 2.8-fold decrease in HP-1 cells 
(p = 0.003) (Fig. 5A).
Similarly, in matrigel invasion assays, at 24 hours, 2 µg/
ml of blocking peptide revealed a 2.0-fold decrease in cell 
invasion for H2595 cells (p = 0.0002) and a 1.6-fold decrease 
in HP-1 cells (p = 3.41E-05) (Fig. 5B). All the fold changes 
were calculated in comparison with treated controls.
DISCUSSION
Despite progress in identifying the molecular changes in 
MM, no targeted therapy has yet proven consistently effective 
in MM. EPH receptors and their ligands, EPHs, form the larg-
est subfamily of tyrosine kinases and were initially identified 
as neuronal path-finding molecules, which guide migrating 
cells to specific tissue targets that are essential in embryonic 
development, vascular cell assembly, and angiogenesis.6 Their 
functions have mainly been studied with respect to cell-to-cell 
interaction, migration, motility, and angiogenesis. Increasing 
evidence points to the involvement of EPH receptors and EPH 
ligands in cancer progression, although their exact role is still 
unknown; however, surprisingly, the receptors and ligands 
have both tumor promoter and suppressor functions in differ-
ent cellular contexts.25–29 Overexpression of some members of 
EPH receptor family has an important role in the development 
and progression of various cancers. In particular, EPHB2 
overexpression is frequently associated with human invasive 
cancers.
This report details that that EPHB2 is overexpressed in 
MM cell lines as well as in tumor samples. MM is character-
ized by extensive local growth and invasion of intrathoracic 
organs. This kind of tumor growth suggests the degradation 
of the extracellular matrix and basement membrane by pro-
teases such as MMPs in the course of the disease. It has been 
shown that  stromal modifications, such as proteolysis of the 
extracellular matrix and basement  membrane, are mediated 
by MMPs. MMPs are a family of zinc-dependent enzymes, 
which are implicated in the growth of primary and second-
ary tumors.30 MMPs play a significant role in tumor invasion 
and angiogenesis. MMPs, in particular gelatinase A (MMP-
2) and gelatinase B (MMP-9) are overexpressed in MM.31–33 
Our findings indicate that EPHB2 may modulate expression 
of MMP-2.
Caspases, a family of cysteine proteases, play a criti-
cal role in the execution of apoptosis, an evolutionary con-
served ATP-dependent type of programmed cellular death 
process.34–38 They are synthesized as proenzymes that are pro-
cessed by self-proteolysis and/or cleavage by other protease 
members to their active forms in cells under process of apop-
tosis. Apoptosis can be triggered by either intrinsic or extrinsic 
death signals and is regulated by two gene families, Bcl2 and 
IAP. The Bcl-2 protooncogene can block apoptotic cell death 
FIGURE 2.  Targeted knockdown of EPHB2 with shRNA 
results in a significant decrease in EPHB2 protein expression 
(A) in H2595 and HP-1 cells. B, Immunofluorescence studies 
demonstrate decreased EPHB2 expression in H2595 and HP-1 
MM cells after expression of its specific shRNA. EPHB2, ephrin 
B2 receptor. 
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either by regulation of free radical generation39 or by blocking 
cyctochrome C release.40 BIRC5/Survivin is a member of the 
inhibitor of apoptosis protein (IAP) family and also acts as 
an important antagonist of apoptosis and has been reported 
to be elevated in MM.41,42 Manipulating members of EPH 
receptor family may induce apoptosis as it has been shown 
that silencing EPH receptors induces apoptosis in MM.21,22,42 
In our study, we have shown that knockdown of EPHB2 essen-
tially is apoptosis inducing, in that the expression of caspase 
1 and caspase 8 become significantly elevated and the levels 
FIGURE 3. A, qRT-PCR and Western 
blot analysis of EPHB2 downstream 
genes: Targeted knockdown of 
EPHB2 expression by its shRNA 
causes an increased expression of 
caspase 1 and caspase 8 mRNA 
(A) and protein (B). A decreased 
expression of BCL2L1, BIRC5, matrix 
metalloproteinase, and vascular 
endothelial growth factor mRNA (A) 
and protein (B) is noticed in H2595 
and HP-1 cells. C, Caspase-8 activity: 
A significant increase in the caspase-8 
activity in apoptotic cells is seen after 
forced expression of EPHB2-shRNA in 
H2595 and HP-1 cells compared with 
scrambled control. Peptidylproplyl 
isomerase A gene was used as a 
normalization control in both semi 
and qRT-PCR analysis. EPHB2, ephrin 
B2 receptor; qRT-PCR, quantitative 
reverse transcriptase polymerase 
chain reaction; EPHB2, ephrin B2 
receptor.
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FIGURE 4.  Biological significance of EPHB2 in MM is demonstrated in in vitro functional assays after suppression of EPHB2 
expressions by its shRNA. A, Cell-proliferation assay: a significant decrease in cell proliferation with a fold change of 1.4-fold to 
2.0-fold (p < 0.001) was noticed in both H2595 and HP-1 cells. B, Scratch closure assay: a reduction in horizontal migration 
by 29% (p < 0.0005) in H2595 and 25% (p < 0.0005) in HP-1 is noticed. C, Cell invasion is significantly decreased in H2595 
by 2.3-fold to 2.7-fold (p < 2.00E-05) and in HP-1 by 1.5-fold to 1.7 fold (p < 2.00E-05) compared with scrambled controls. 
D, Colony formation: significant decrease in the size and number of colonies was noted in both H2595 and HP-1 MM cells. 
However, no significant changes were noticed in LP9 cells. EPHB2, ephrin B2 receptor, MM, malignant mesothelioma. 
FIGURE 5.  Blocking peptide and 
antibody experiments in H2595 and 
HP-1 cells show a significant decrease 
in cell proliferation (A) and invasion 
(B). EPHB2, ephrin B2 receptor.
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of Bcl-2 and survivin are decreased. Hence, it is theoretically 
possible to modulate MM viability through manipulations 
of EPHB2.
EPH receptors and EPH ligands play an important 
role in the metastatic process not only by affecting migra-
tion, apoptosis, and, but also through angiogenesis.43,44 It has 
been shown that some growth factors play an important role 
in the growth and metastasis of MM such as platelet-derived 
growth factor (PDGF)-B, insulin-like growth factor (IGF)-
1, transforming growth factor (TGF)-a, interleukin (IL-8), 
VEGF, and VEGF-C45–48 of which IL-8 and VEGF are potent 
angiogenic factors.49,50 Elevated levels of EPHB2 in MM 
may regulate VEGF expression, and our results demonstrate 
a decrease in VEGF expression with reduced EPH receptor 
B2 activity.
In conclusion, EPHB2 is overexpressed in MM, and it 
inhibition has profound in vitro effects on the invasive aspects 
of the disease as well as on apoptosis control. Therefore, tar-
geting EPHB2 might provide a novel therapy to improve the 
prognosis in people suffering from MM. Further investiga-
tion in vitro using specific inhibitors of EPHB2 is required 
to determine the importance of EPHB2 and its interactions 
with other members of the receptor kinases and their ligands 
to prove its role as a marker of progression and metastasis 
for MM.
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